secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001804220-23-000029
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron Q3 revenue $3.36B (+15%); GAAP EPS $8.89, non-GAAP EPS $11.59; EYLEA HD launch begins
--------------------------------------------------------------------------------

- Revenue $3.363B (+15% YoY); GAAP EPS $8.89, non-GAAP EPS $11.59.
- EYLEA HD launched post-FDA approval, generated $43M U.S. net sales in Q3.
- Dupixent global net sales (Sanofi) $3.10B (+33% YoY); Libtayo global net sales $232M (+62%).
- FDA accepted priority reviews for odronextamab in FL/DLBCL and Dupixent in pediatric EoE; CRL for Dupixent in CSU.
- CFO Robert Landry to retire Feb 2024; Christopher Fenimore to succeed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000180422023000029/0001804220-23-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000180422023000029/regn-20231102.htm
  HTML page:      https://secwatch.observer/filing/0001804220-23-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer